跳至主要内容
临床试验/NCT04874961
NCT04874961已完成4 期

Olive Polyphenols in Cardiovascular Prevention: Efficacy and Tolerability of a Commercially Available Standardized Olive Extract (Tensiofytol®) as Compared to Placebo in Patients With Elevated Blood Pressure: a RDBPC Trial.

Nina Hermans1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2021年5月20日最近更新:
适应症

试验速览

阶段
4 期
状态
已完成
发起方
Nina Hermans
入组人数
56
试验地点
1
主要终点
Change from baseline Blood Pressure, Systolic at 8 weeks

研究概览

简要总结

The aim of this study is to evaluate whether the use of a commercially available standardized olive extract (Tensiofytol®) in individuals with elevated blood pressure

  1. Leads to a clinically relevant reduction of blood pressure on the short term,
  2. Leads to a clinically relevant reduction of cholesterol levels, especially LDL,
  3. Leads to a change in oxidative stress biomarkers.

Participants will be stratified by sex before randomization to one of the three treatments for 8 weeks:

  • Tensiofytol: 100 mg oleuropein and 20 mg hydroxytyrosol per day
  • Placebo

All treatments have an identical shape and color and should be used in the same way (oral intake; 3 capsules/day during dinner). No dietary instructions are given and participants are asked not to change their dietary habits, nor to start other therapies (medication, supplements, slimming diets, extra physical activity, etc.) during their study period. Standardized questionnaires are used to obtain information on demographics, dietary habits and side effects. At baseline and after 8 weeks, 27 ml blood is drawn for various biological analyses, and blood pressure, BMI and waist circumference are measured.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 76 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Systolic blood pressure ≥ 130 mmHg

排除标准

  • <18 jaar
  • >76 jaar
  • Use of nutritional supplements or (chronic) medication*
  • Triglycerides > 400 mg/dL
  • > 14 alcoholic consumptions/week
  • Chronic illness (e.g. diabetes, atherosclerosis, reumatoid arthritis)
  • Acute infection
  • Current pregnancy or pregnancy wish during the study period
  • Breast feeding
  • When nutritional supplements were used regularly, participation is allowed after a 10-day wash out period.
  • Use of medication will be individually assessed and is permitted if it does not interfere with the used treatments and the patient is stable on the medication.

结局指标

主要结局

Change from baseline Blood Pressure, Systolic at 8 weeks

时间窗: Baseline, 8 weeks

average of 3 measurements during 15 minutes

次要结局

  • Change from baseline Blood Pressure, systolic at 4 weeks(Baseline, 4 weeks)
  • Change from baseline OxLDL level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline HDL cholesterol level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline total cholesterol level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline triglycerides level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline gluathion (GSH) level at 8 weeks(Baseline, 8 weeks)
  • Frequency of side effects (+ their burden) as reported in the final questionnaire(8 weeks)
  • Change from baseline LDL cholesterol level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline Apo A1 level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline Apo B level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline malondialdehyde (MDA) level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline Blood Pressure, diastolic at 8 weeks(Baseline, 8 weeks)
  • Change from baseline non-HDL cholesterol level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline lipoprotein A (LP(a)) level at 8 weeks(Baseline, 8 weeks)
  • Change from baseline Remnant Cholesterol at 8 weeks(Baseline, 8 weeks)

研究者

发起方
Nina Hermans
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Nina Hermans

Professor

Universiteit Antwerpen

研究点 (1)

Loading locations...

相似试验